> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lupin Gets Another Form-483 After India Inspection
- URL: https://www.fdaweb.com/lupin-gets-another-form-483-after-india-inspection/
- Published: 2016-03-16T12:00:00.000Z
- Updated: 2026-09-15T02:44:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135101

> Lupin has acknowledged that FDA completed an inspection last week at its Goa, India manufacturing plant. The agency issued a nine-item Form-483 related to “inadequacy and adherence to SOPs,” the company says, adding that it is preparing a response. The Goa facility manufactures a range of finished products for the U.S. market including oral and injectable drugs.  
>  
> A year ago, FDA issued a six-observation Form-483 after it audited Lupin’s Pithampur in Madhya Pradesh drug manufacturing facility. The plant reportedly produces both oral contraceptives and ophthalmic treatments for the U.S. market.